Adamas Pharmaceuticals Inc (ADMS) is Reiterated by Mizuho to Neutral, Raises Price Target to $ 17

Adamas Pharmaceuticals Inc (ADMS) was Reiterated by Mizuho to “Neutral” according to the research note released today. The brokerage firm has raised the Price Target to $ 17 from a previous price target of $14 . Mizuho advised their investors in a research report released on Apr 28, 2016.

Many Wall Street Analysts have commented on Adamas Pharmaceuticals Inc. Adamas Pharmaceuticals Inc was Initiated by JMP Securities to “Mkt Outperform” on Apr 1, 2016.

Adamas Pharmaceuticals Inc closed down -0.12 points or -0.68% at $17.5 with 4,46,772 shares getting traded on Wednesday. Post opening the session at $17.55, the shares hit an intraday low of $17.25 and an intraday high of $18 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Apr 20, 2016, Natalie Mcclure (SVP, Product Development) sold 36,000 shares at $18.50 per share price. According to the SEC, on Dec 9, 2015, Ivan M Lieberburg (director) sold 3,000 shares at $16.23 per share price. On Jun 17, 2015, Richard H Booth (director) sold 1,000 shares at $19.32 per share price, according to the Form-4 filing with the securities and exchange commission.

Adamas Pharmaceuticals Inc. is a specialty pharmaceutical company focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems (CNS). It is engaged in modifying pharmacokinetic (PK) profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. It develops its lead product ADS-5102 (amantadine hydrochloride) for a complication associated with treatment of Parkinson’s disease known as levodopa induced dyskinesia and as a treatment for one or more additional CNS indications. Its other product candidate is ADS-8704. Through a partnership with Forest Laboratories Holdings Limited its portfolio includes two drugs commercially available in the United States: Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release capsules.

Adamas Pharmaceuticals Inc

Leave a Reply

Adamas Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Adamas Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.